Caplin Point Laboratories Q3 Review - In-Line; Outlook Positive Amid Expansion Plans: ICICI Direct

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Direct Report.Caplin Point Laboratories Ltd.'s revenues grew 18.9% YoY to Rs 326.2 crore mainly on the back of the company’s unique end to end business model in Latin America. Ebitda margins were steady YoY at 31% while Ebitda grew 20.3% YoY to Rs 101 crore. Adjusted profit after tax grew 16.3% YoY to Rs 75 crore.Caplin’s core business in Latin America and Africa delivered strong growth amid challenging landscape in logistics while Caplin Steriles nine months-FY22 sales has overtaken FY21 revenues and has set a target of $100 million by CY26 in U.S. The company is undergoing a capex journey of Rs 430-450 crore to expand existing capacities, widen its product portfolio and backward integrate majority of the products. Caplin plans to enter more regulated markets such as Canada, Australia, China, Russia/Commonwealth of Independent States as well as enter the bigger LatAm markets of Mexico and Brazil in the near to medium term horizon..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Caplin Point Laboratories Q3 Review - In-Line; Outlook Positive Amid Expansion Plans: ICICI Direct